<DOC>
	<DOCNO>NCT00240305</DOCNO>
	<brief_summary>The purpose study investigate dose-related effect treatment rosuvastatin production fractional catabolism apolipoprotein A-I ( apoA-I ) apolipoprotein A-II ( apoA-II ) , plasma apoA-I , apoA-II high-density lipoprotein cholesterol ( HDL-C ) concentration .</brief_summary>
	<brief_title>A Study Investigate Effect Rosuvastatin ( CRESTOR® ) High Density Lipoprotein Kinetics Patients With Metabolic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Signed informed consent male age 30 70 year age LDLC &lt; 6 mmol/L HDLC ≤1.2 mmol/L least 2 follow : insulin resistance ( fast glucose &gt; 6 mmol/L insulin &gt; 10 mU/L HOMA score &gt; 2.5 ) central obesity ( waist circumference &gt; =94 cm ) . plasma triglyceride &gt; =1.7 &lt; 4.5 mmol/L . blood pressure &gt; =130/ &gt; =85 mm Hg drug treatment hypertension LDL cholesterol &gt; =6 mmol/L preexist history cardiovascular disease , diabetes , renal dysfunction , anaemia , history significant dyspepsia gastrointestinal disease apolipoprotein genotype E2/E2</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Metabolic Syndrome</keyword>
	<keyword>Dyslipidaemia</keyword>
</DOC>